Diagnostic value of CD34 immunostaining in desmoplastic trichilemmoma

Illueca, Carlos; Monteagudo, Carlos; Revert, Ángeles; Llombart‐Bosch, Antonio

doi:10.1111/j.1600-0560.1998.tb01770.x

Cited by 64 publications

(62 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[2][3][4][5][6][7][8][9][10][11][12][13][14][15] With exception of D2-40 labeling, 14 the studies present conflicting findings when comparing results for the same immunohistochemical markers. This may be due to the small number of basaloid tumors that comprised their casuistics.…”

mentioning

confidence: 65%

Diagnostic utility of immunohistochemistry in distinguishing trichoepithelioma and basal cell carcinoma: evaluation using tissue microarray samples

2012

View full text Add to dashboard Cite

Trichoepithelioma is a benign neoplasm that shares both clinical and histological features with basal cell carcinoma. It is important to distinguish these neoplasms because they require different clinical behavior and therapeutic planning. Many studies have addressed the use of immunohistochemistry to improve the differential diagnosis of these tumors. These studies present conflicting results when addressing the same markers, probably owing to the small number of basaloid tumors that comprised their studies, which generally did not exceed 50 cases. We built a tissue microarray with 162 trichoepithelioma and 328 basal cell carcinoma biopsies and tested a panel of immune markers composed of CD34, CD10, epithelial membrane antigen, Bcl-2, cytokeratins 15 and 20 and D2-40. The results were analyzed using multiple linear and logistic regression models. This analysis revealed a model that could differentiate trichoepithelioma from basal cell carcinoma in 36% of the cases. The panel of immunohistochemical markers required to differentiate between these tumors was composed of CD10, cytokeratin 15, cytokeratin 20 and D2-40. The results obtained in this work were generated from a large number of biopsies and resulted in the confirmation of overlapping epithelial and stromal immunohistochemical profiles from these basaloid tumors. The results also corroborate the point of view that trichoepithelioma and basal cell carcinoma tumors represent two different points in the differentiation of a single cell type. Despite the use of panels of immune markers, histopathological criteria associated with clinical data certainly remain the best guideline for the differential diagnosis of trichoepithelioma and basal cell carcinoma.

show abstract

mentioning

confidence: 65%

Diagnostic utility of immunohistochemistry in distinguishing trichoepithelioma and basal cell carcinoma: evaluation using tissue microarray samples

2012

View full text Add to dashboard Cite

show abstract

“…Therefore, it has been claimed that the CD34 + fibrocyte may play an important role in host response to tissue damage of whatever cause. By means of immunohistochemistry, CD34 + fibrocytes have been detected in the skin [14] -in cutaneous [4,5,7,8,21] and lipomatous tumors [18,20] -and in a multitude of mesenchymal tumors [11,15,18,19]. However, it remains to be clarified to what extent CD34 + fibrocytes observed in various organs are derived from circulating CD34 + fibrocytes.…”

Section: Introductionmentioning

confidence: 99%

CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions

et al. 2001

View full text Add to dashboard Cite

The present study was undertaken in order to elucidate the question of whether the distribution of stromal CD34+ fibrocytes and smooth muscle actin (SMA)-reactive myofibroblasts differs between benign and malignant lesions of the breast. We investigated a total of 31 ductal carcinomas and 27 specimens with benign lesions of the breast (ductal hyperplasia, sclerosing adenosis, fibroadenoma, phyllodes tumor) and compared the distribution of CD34+ fibrocytes and SMA-reactive myofibroblasts. The stroma of normal breast tissue contained CD34+ fibrocytes, whereas SMA-reactive myofibroblasts were absent. All benign breast lesions exhibited stromal CD34+ fibrocytes and few lesions (fibroadenomas and phyllodes tumor) showed additional SMA-reactive myofibroblasts. In invasive breast cancer the stroma was devoid of CD34+ fibrocytes but a varying number of stromal SMA-reactive myofibroblasts was detectable. In the setting of the present study the loss of CD34+ fibrocytes was specific for invasive breast cancer and ductal carcinoma in situ, whereas SMA-reactive myofibroblasts were observed in different benign and malignant lesions. These findings may be helpful tools in distinguishing benign breast lesions (e.g., sclerosing adenosis) from invasive breast cancer and in characterizing stromal remodeling associated with invasive cancer.

show abstract

“…In difficult cases however, the CD 34 positive and BerEP4 negative immunostaining of the epithelial cells allow to definitely clarify diagnosis and rule out BCC. 16 In our patient`s case, as opposed to the non-specific clinical presentation, the pathological examination allowed to clearly diagnose DTr within a nevus sebaceous.…”

Section: Discussionmentioning

confidence: 77%

Triquilemoma Desmoplástico em Nevo Sebáceo do Couro Cabeludo

Tavares‐Bello

Fernandes

2016

SPDV

View full text Add to dashboard Cite

RESUMO -Descrito originalmente por Jadassohn em 1895, foi apenas em 1932 que a designação "nevo sebáceo" foi introduzida, por Robinson. Trata-se de um hamartoma congénito relativamente prevalente que, classicamente, evolui por fases de crescimento e maturação (classicamente estão descritas 3 fases: infância <12; adolescência 12-18; adultos >18) e que, do 4º ao 7º decénios pode originar, em 10-30% dos casos), várias neoplasias epiteliais. Muito raramente reportados neste contexto, os triquilemomas são tumores anexiais benignos que se originam ou diferenciam no epitélio da bainha radicular externa folicular. Habitualmente solitários, podem apresentar-se clinicamente como pápulas translúcidas ou queratósicas faciais, em particular na proximidade da pirâmide nasal e dos lábios. A rara variante histológica "triquilemoma desmoplásico" pode simular clinicamente basaliomas (CBC), carcinomas espinhocelulares (CEC), nevos intradérmicos, verrugas virais, cornos cutâneos ou hiperplasias sebáceas e, histologicamente, evocar variantes desmoplásicas de CBCs, CECs e de carcinomas triquilémicos. É apresentado caso de doente eurocaucasiano de 56 anos de idade que apresentava pápulas e nódulos translúcidos assintomáticos, desenvolvidos num nevo sebáceo do couro cabeludo. O estudo histológico revelou uma proliferação lobular com as características clássicas do triquilemoma desmoplásico no seio de um hamartoma sebáceo. O caso é ilustrado iconograficamente e a literatura relevante é sumariamente revista. PALAVRAS-CHAVE -Nevo; Neoplasias das Glândulas Sebáceas; Neoplasias da Pele. Desmoplastic Trichilemmoma arising on a Nevus Sebaceous of the Scalp ABSTRACT -Originally described by Jadassohn in 1895, it was not until 1932 that the term "nevus sebaceous" was introduced by Robinson. It is a prevalent benign congenital hamartoma that classically evolves through discrete phases of growth and that

show abstract

Diagnostic value of CD34 immunostaining in desmoplastic trichilemmoma

Cited by 64 publications

References 9 publications

Diagnostic utility of immunohistochemistry in distinguishing trichoepithelioma and basal cell carcinoma: evaluation using tissue microarray samples

Diagnostic utility of immunohistochemistry in distinguishing trichoepithelioma and basal cell carcinoma: evaluation using tissue microarray samples

CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions

Triquilemoma Desmoplástico em Nevo Sebáceo do Couro Cabeludo

Contact Info

Product

Resources

About